摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5'-[diphenyl(4-pyridyl)methyl]amino-2',5'-dideoxyuridine | 859206-63-6

中文名称
——
中文别名
——
英文名称
5'-[diphenyl(4-pyridyl)methyl]amino-2',5'-dideoxyuridine
英文别名
1-[(2R,4S,5R)-5-[[[diphenyl(pyridin-4-yl)methyl]amino]methyl]-4-hydroxyoxolan-2-yl]pyrimidine-2,4-dione
5'-[diphenyl(4-pyridyl)methyl]amino-2',5'-dideoxyuridine化学式
CAS
859206-63-6
化学式
C27H26N4O4
mdl
——
分子量
470.528
InChiKey
HOQCEXHNNSUTEO-JBRSBNLGSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    35
  • 可旋转键数:
    7
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.22
  • 拓扑面积:
    104
  • 氢给体数:
    3
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    2-脱氧尿苷吡啶 、 sodium azide 、 5%-palladium/activated carbon 、 氢气三乙胺 作用下, 以 乙醇N,N-二甲基甲酰胺 为溶剂, 反应 35.0h, 生成 5'-[diphenyl(4-pyridyl)methyl]amino-2',5'-dideoxyuridine
    参考文献:
    名称:
    修饰的5'-Trityl核苷作为恶性疟原虫dUTPase的抑制剂
    摘要:
    2'-脱氧尿苷三磷酸核苷酸水解酶(dUTPase)是治疗疟疾的潜在药物靶标。我们之前曾报道过发现脱氧尿苷的5'-三苯甲基化类似物可作为恶性疟原虫的选择性抑制剂酶。在这里,我们报告了进一步的结构活动研究;特别是5'-三苯甲基的变体,在脱氧尿苷的3'-位置引入了各种取代基以及修饰了碱基。测试了针对酶和寄生虫的化合物。5'-三苯甲基和3'-取代基的变异具有良好的耐受性,并产生了活性化合物。然而,由于尿嘧啶环的修饰导致酶抑制作用的丧失和抗血浆作用的显着降低,因此对尿嘧啶碱基的活性有明确的要求。
    DOI:
    10.1002/cmdc.201000445
点击查看最新优质反应信息

文献信息

  • Dutpase Inhibitors
    申请人:Gilbert Ian
    公开号:US20080300216A1
    公开(公告)日:2008-12-04
    Deoxyuridine derivatives of Formula (I′); where A is O, S or CH 2 ; B is O, S or CHR 3 ; R 1 is H, or various substituents; R 2 is H, F; R 3 is H, F, OH, NH 2 ; or R 2 and R 3 together form a chemical bond; D is —NHCO—, —CONH—, —O—, —C(═O)—, —CH═CH, —C≡C—, —NR 5 —; R 4 is hydrogen or various substituents; R 5 is H, C 1 -C 4 alkyl, C 1 -C 4 alkanoyl; E is Si or C; R 6 , R 7 and R 8 are independently selected from C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, or a stable monocyclic, bicyclic or tricyclic ring system have utility in the prophylaxis of treatment of parasitic diseases such as malaria.
    化合物(I')的脱氧尿嘧啶衍生物;其中A为O、S或CH2;B为O、S或CHR3;R1为H或各种取代基;R2为H、F;R3为H、F、OH、NH2;或R2和R3共同形成化学键;D为-NHCO-、-CONH-、-O-、-C(═O)-、-CH═CH、-C≡C-、-NR5-;R4为氢或各种取代基;R5为H、C1-C4烷基、C1-C4酰基;E为Si或C;R6、R7和R8分别选择自C1-C8烷基、C2-C8烯基、C2-C8炔基或稳定的单环、双环或三环环系统,在预防或治疗疟疾等寄生虫病方面具有用途。
  • DUTPASE INHIBITORS
    申请人:Gilbert Ian
    公开号:US20100075924A1
    公开(公告)日:2010-03-25
    Deoxyuridine derivatives of the formula where A is O, S or CH 2 ; B is O, S or CHR 3 ; R 1 is H, or various substituents; R 2 is H, F; R 3 is H, F, OH, NH 2 ; or R 2 and R 3 together form a chemical bond; D is —NHCO—, —CONH—, —O—, —C(═O)—, —CH═CH, —C ═ C—, —NR 5 —; R 4 is hydrogen or various substituents; R 5 is H, C 1 -C 4 alkyl, C 1 -C 4 alkanoyl; E is Si or C; R 6 , R 7 and R 8 are independently selected from C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, or a stable monocyclic, bicyclic or tricyclic ring system have utility in the prophylaxis o treatment of parasitic diseases such as malaria
    Deoxyuridine衍生物的公式为: 其中A为O、S或CH2;B为O、S或CHR3;R1为H或各种取代基;R2为H、F;R3为H、F、OH、NH2;或R2和R3共同形成化学键;D为—NHCO—、—CONH—、—O—、—C(═O)—、—CH═CH、—C═C—、—NR5—;R4为氢或各种取代基;R5为H、C1-C4烷基、C1-C4酰基;E为Si或C;R6、R7和R8分别选自C1-C8烷基、C2-C8烯基、C2-C8炔基或稳定的单环、双环或三环环系统。 具有预防或治疗疟疾等寄生虫病的功效。
  • US7601702B2
    申请人:——
    公开号:US7601702B2
    公开(公告)日:2009-10-13
  • [EN] DUTPASE INHIBITORS<br/>[FR] INHIBITEUR DES DUTPASES
    申请人:MEDIVIR AB
    公开号:WO2005066160A1
    公开(公告)日:2005-07-21
    Deoxyuridine derivatives of Formula (I’); where A is O, S or CH2; B is O, S or CHR3; R1 is H, or various substituents; R2 is H, F; R3 is H, F, OH, NH2 ; or R2 and R3 together form a chemical bond; D is -NHCO-, -CONH-, -0-, -C(=O)-, -CH=CH, -C≡C-, -NR5-; R4 is hydrogen or various substituents; R5 is H, C1-C4 alkyl, C1-C4 alkanoyl; E is Si or C; R6, R7 and R8 are independently selected from C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, or a stable monocyclic, bicyclic or tricyclic ring system have utility in the prophylaxis o treatment of parasitic diseases such as malaria.
  • Modified 5′-Trityl Nucleosides as Inhibitors of<i>Plasmodium falciparum</i>dUTPase
    作者:Gian Filippo Ruda、Corinne Nguyen、Przemysław Ziemkowski、Krzysztof Felczak、Ganasan Kasinathan、Alexander Musso-Buendia、Christian Sund、Xiao Xiong Zhou、Marcel Kaiser、Luis M. Ruiz-Pérez、Reto Brun、Tadeusz Kulikowski、Nils Gunnar Johansson、Dolores González-Pacanowska、Ian H. Gilbert
    DOI:10.1002/cmdc.201000445
    日期:2011.2.7
    2′‐Deoxyuridine triphosphate nucleotidohydrolase (dUTPase) is a potential drug target for the treatment of malaria. We previously reported the discovery of 5′‐tritylated analogues of deoxyuridine as selective inhibitors of this Plasmodium falciparum enzyme. Herein we report further structure–activity studies; in particular, variations of the 5′‐trityl group, the introduction of various substituents
    2'-脱氧尿苷三磷酸核苷酸水解酶(dUTPase)是治疗疟疾的潜在药物靶标。我们之前曾报道过发现脱氧尿苷的5'-三苯甲基化类似物可作为恶性疟原虫的选择性抑制剂酶。在这里,我们报告了进一步的结构活动研究;特别是5'-三苯甲基的变体,在脱氧尿苷的3'-位置引入了各种取代基以及修饰了碱基。测试了针对酶和寄生虫的化合物。5'-三苯甲基和3'-取代基的变异具有良好的耐受性,并产生了活性化合物。然而,由于尿嘧啶环的修饰导致酶抑制作用的丧失和抗血浆作用的显着降低,因此对尿嘧啶碱基的活性有明确的要求。
查看更多

同类化合物

鲁西他滨 化合物 T14195 [1,1'-联苯基]-2,3,3',4,4',5'-六醇 [(2R,3R,5S)-3-(氨基甲基)-5-(5-甲基-2,4-二氧代嘧啶-1-基)四氢呋喃-2-基]N-[[(2R,3S,5R)-3-羟基-5-(5-甲基-2,4-二氧代嘧啶-1-基)四氢呋喃-2-基]甲基]氨基甲酸酯 9-(2-S-苯甲基-5-脱氧-2-硫代五呋喃糖基)-9H-嘌呤-6-胺 5-脱氧胸苷 5-脱氧-5-[(碘乙酰基)氨基]-胸腺嘧啶脱氧核苷 5-碘-5-脱氧胸腺嘧啶脱氧核苷 5-氨基-5-脱氧胸腺嘧啶脱氧核苷 5-氨基-2,5-二脱氧腺苷酸 5-叠氮基-5-脱氧胸腺嘧啶脱氧核苷 5-三氟乙酰氨基-5-脱氧胸腺嘧啶脱氧核苷 5'-脱氧-5'氟胸苷 5'-脱氧-5'-{[4-(甲硫基)苯胺基羰基]氨基}胸苷 5'-脱氧-5'-{[3-(甲硫基)苯胺基羰基]氨基}胸苷 5'-脱氧-5'-[4-苯基-(1,2,3)三唑-1-基]胸苷 5'-脱氧-5'-[4-(吡啶-3-基)-(1,2,3)三唑-1-基]胸苷 5'-脱氧-5'-[4-(4-氟苯基)-(1,2,3)三唑-1-基]胸苷 5'-硫代-胸苷3',5'-二乙酸酯 5'-溴乙酰氨基-5'-脱氧胸苷 5'-氨基-5-碘-2',5'-二脱氧尿苷 2-氯-N-[[3-羟基-5-(5-甲基-2,4-二氧代嘧啶-1-基)四氢呋喃-2-基]甲基]乙酰胺 2,5-二脱氧腺苷 2',5'-二脱氧尿苷 1-[(2R,4S,5R)-4-羟基-5-(异氰基甲基)四氢呋喃-2-基]嘧啶-2,4-二酮 1-[(2R,4S,5R)-4-羟基-5-(异氰基甲基)四氢呋喃-2-基]-5-甲基嘧啶-2,4-二酮 1-(2,5-二脱氧-2-氟-β-D-呋喃阿拉伯糖基)嘧啶-2,4(1H,3H)-二酮 1-(2,5-二脱氧-2-氟-β-D-呋喃阿拉伯糖基)-5-碘嘧啶-2,4(1H,3H)-二酮 1-citosin-1-yl-1,2,5-trideoxy-α-L-threo-pentofuranos-4-yloxymethylphosphonic acid 9-[2,5-dideoxy-2-fluoro-5-[N-(N-2-hydroxybenzoyl)sulfamoyl]amino-β-D-ribofuranosyl]adenine triethylammonium salt 5'-amino-2',5'-dideoxy-2'-fuorouridine 1-(5'-deoxythymidin-5'-yl)-4-[methyloxycarbonyl-(2'-deoxy-2',2'-difluorocytidin-4N-yl)]-1H-1,2,3-triazole 2',5'-dideoxy-2'-(3,5-dimethoxybenzamido)-5'-(cyclohexylacetamido)adenosine 2',5'-dideoxy-2'-(3'',5''-dimethoxybenzamido)-5'-(diphenylacetamido)adenosine 2',5'-dideoxy-5'-(hydroxyethylthio)adenosine 1-(5-azido-2,5-dideoxy-2-fluoro-β-D-arabinofuranosyl)-5-ethyluracil 1-(5'-deoxythymidin-5'-yl)-4-[methyl-(2'-deoxy-2',2'-difluorocytidin-4N-yl)]-1H-1,2,3-triazole 4′-C-azidomethyl-2′-deoxy-2′-fluorouridine 2',5'-dideoxy-6-thioguanosine thymidylyl (3'-5') 5'-seleno-5'-deoxythymidine 3'-O-(t-butyldimethylsilyl)-4'-α-methylthymidine (E)- and (Z)-5-(2-bromovinyl)-1-(5-chloro-2,5-dideoxy-β-D-erythro-pentofuranosyl)-5-methyl-4-(1,2,4-triazol-1-yl)pyrimidin-2(1H)-one N-<1,2,5-trideoxy-1β-(5-fluoro-1,2,3,4-tetrahydro-2,4-dioxopyrimidin-1-yl)-D-ribofuranos-5-yl>succinamic acid N-butyl-N'-<1,2,5-trideoxy-1β-(5-fluoro-1,2,3,4-tetrahydro-2,4-dioxopyrimidin-1-yl)-D-ribofuranose-5-yl>maleamide N-<1,2,5-trideoxy-1β-(5-fluoro-1,2,3,4-tetrahydro-2,4-dioxopyrimidin-1-yl)-D-ribofuranos-5-yl>maleamic acid 4'-chloromethyl-2'-deoxy-2',2'-difluorocytidine 4'-chloromethyl-2'-deoxy-2'-fluoro-3'-O-(L-valinyl)cytidine dihydrochloride 5'-deoxy-5'-{4-[2-(3-oxo-3H-benzo[f]chromen-1-yl)acetamidomethyl]-1H-1,2,3-triazol-1-yl}thymidine N6-benzoyl-3'-O-t-butyldimethylsilyl-5'-sulfamoylazido-2',5'-dideoxyadenosine N-{9-[(2R,4S,5R)-5-(Acetylamino-methyl)-4-hydroxy-tetrahydro-furan-2-yl]-9H-purin-6-yl}-benzamide